Fig 1.
Doxorubicin/Paclitaxel (AT); Eribulin (E). One patient did not complete the pre planned treatment with AT x 4 cycles followed by E x 4 cycles, as she underwent surgery soon after the second cycle of E, due to progressive disease.
Table 1.
Patients and tumor characteristics.
Table 2.
Main toxicities.
Table 3.
Clinical and pathological treatment response to E following AT.
Fig 2.
Box- plot of SUV max in TNBC patients at baseline, after treatment with AT, and after E.
The boxes represent the 25–75% range with bisecting lines showing the median values, and the horizontal lines represent the 10–90% range.
Fig 3.
Epithelial to mesenchymal transition biomarker levels in primary tumor samples.
Spaghetti plot of the changes of primary tumor immunostaining of individual patients at baseline and after study treatment with neoadjuvant AT followed by E. Immunostaining for the indicated biomarkers was performed on 13 primary tumor specimes, specifically 8 pre-treatment, 5 post-treatment, and 5 paired-biopsies (missing information at surgery in 3 cases: 1 pCR, 2 insufficient amount of residual tumor). Five patients are not represented due to lack of evaluable primary tumor tissue at both baseline and at surgery. Epithelial–mesenchymal transition (EMT); EMT scores, estimated as reported in the Methods section.
Fig 4.
Specific reaction with β-catenin, N-cadherin, Cylin D1, c-myc and Zeb-1 monoclonal antibodies in primary TNBC before and after neoadjuvant therapy with AT followed by E. Intense immunostaining was evident in pre-treatment primary tumor biopsy, whereas it appeared reduced in surgical specimen after study treatment, with the unique exception of N-cadherin, whose levels remained stable. Scale bar, reported at the right bottom of each picture.